Pharmacokinetic and Pharmacodynamic Properties of Oral Voriconazole in Patients with Invasive Fungal Infections
暂无分享,去创建一个
J. Xing | Qianting Yang | J. Lei | Jiao Xie | Taotao Wang | Yalin Dong | Yan Wang | Limei Chen | Xue Wang | Haiyan Dong | Xiaowei Zheng | Jiao Xie | Jianfeng Xing
[1] F. Dromer,et al. Population-Based Analysis of Invasive Fungal Infections, France, 2001–2010 , 2014, Emerging infectious diseases.
[2] R. Gorton,et al. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. , 2014, The Journal of antimicrobial chemotherapy.
[3] J. Xing,et al. Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections. , 2014, The Journal of antimicrobial chemotherapy.
[4] M. Valach,et al. Fungal neuroinfections and fungaemia: unexpected increase of mortality from invasive fungal infections in 2005-2011 in comparison to 1989-1998: analysis of 210 cases. , 2013, Neuro endocrinology letters.
[5] P. G. Choe,et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] T. Buclin,et al. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] G. Guaraldi,et al. Fusarium verticillioides fungemia in a liver transplantation patient: successful treatment with voriconazole. , 2011, Diagnostic microbiology and infectious disease.
[8] P. Troke,et al. Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients , 2011, Antimicrobial Agents and Chemotherapy.
[9] M. Pai,et al. Steady-State Plasma Pharmacokinetics of Oral Voriconazole in Obese Adults , 2011, Antimicrobial Agents and Chemotherapy.
[10] M. Romkes,et al. Voriconazole Pharmacokinetics in Liver Transplant Recipients , 2009, Antimicrobial Agents and Chemotherapy.
[11] P. Chandrasekar,et al. Antifungal drugs: predicting clinical efficacy with pharmacodynamics , 2009, Expert review of clinical pharmacology.
[12] Kazuaki Matsumoto,et al. Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes. , 2009, International journal of antimicrobial agents.
[13] M. Kurokawa,et al. Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders , 2009, International journal of hematology.
[14] W. Haefeli,et al. CYP2C19 Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole , 2009, Journal of clinical pharmacology.
[15] Liuda Ziaugra,et al. SNP Genotyping Using the Sequenom MassARRAY iPLEX Platform , 2009, Current protocols in human genetics.
[16] J. Perfect,et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[17] Patricia Muñoz,et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] H. Lipp. Antifungal agents – clinical pharmacokinetics and drug interactions , 2008, Mycoses.
[19] Thierry Buclin,et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[20] S. Ranque,et al. Contribution of the (1→3)-β-d-Glucan Assay for Diagnosis of Invasive Fungal Infections , 2007, Journal of Clinical Microbiology.
[21] L. Gordon,et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients , 2007, Cancer.
[22] K. Sepkowitz,et al. Issues related to the design and interpretation of clinical trials of salvage therapy for invasive mold infection. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] T. Buclin,et al. Variability of Voriconazole Plasma Levels Measured by New High-Performance Liquid Chromatography and Bioassay Methods , 2006, Antimicrobial Agents and Chemotherapy.
[24] Peter G. Pappas,et al. Invasive Fungal Pathogens: Current Epidemiological Trends , 2006 .
[25] R. Herbrecht,et al. Clinical pharmacokinetics of voriconazole. , 2006, International journal of antimicrobial agents.
[26] M. Ghannoum,et al. Correlation of MIC with Outcome for Candida Species Tested against Voriconazole: Analysis and Proposal for Interpretive Breakpoints , 2006, Journal of Clinical Microbiology.
[27] E. Thiel,et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. , 2005, Blood.
[28] S. Balajee,et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. , 2004, The Journal of infectious diseases.
[29] M. Nakashima,et al. Pharmacokinetics of Voriconazole and Cytochrome p450 2C19 Genetic Status , 2004, Clinical pharmacology and therapeutics.
[30] D. Andes,et al. In Vivo Pharmacokinetics and Pharmacodynamics of a New Triazole, Voriconazole, in a Murine Candidiasis Model , 2003, Antimicrobial Agents and Chemotherapy.
[31] D A Smith,et al. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[32] S. Gershon,et al. Effects of chronic chlorpromazine administration on systemic arterial pressure in schizophrenic patients: Relationship of body position to blood pressure , 1965, Clinical pharmacology and therapeutics.
[33] Clinical,et al. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi : Approved standard , 2008 .
[34] Clinical,et al. Reference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard , 2008 .
[35] L. Scott,et al. Voriconazole : a review of its use in the management of invasive fungal infections. , 2007, Drugs.
[36] H. Derendorf,et al. Pharmacokinetic/Pharmacodynamic Profile of Voriconazole , 2006, Clinical pharmacokinetics.